ESMO 2017: Docetaxel and abiraterone acetate plus prednisolone equally improved survival in patients with high-risk prostate cancer: first results from the STAMPEDE trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • A subanalysis of the STAMPEDE trial found that docetaxel and abiraterone acetate plus prednisolone equally improved survival when added to long-term hormone therapy in patients with high-risk prostate cancer.
  • Either drug is acceptable and choice may depend on availability.

Wh...